Company Prostatype Genomics AB

Equities

PROGEN

SE0014684569

Healthcare Facilities & Services

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Company contact information

Sector

Annual profits - Rate of surprise

Sector Medical & Diagnostic Laboratories

Delayed Nasdaq Stockholm Other stock markets 06:49:11 2024-04-30 am EDT			5-day change	1st Jan Change
0.0416 ^SEK	+7.22%		+1.96%	-56.21%

Apr. 18	Prostatype Genomics Announces Very Strong Interim Results from Long-Term Follow-Up Study with Prostatype in Uppsala	CI
Apr. 17	Prostatype Genomics Updates on Significant Progress in the US Study with Prostatype®	CI

Prostatype Genomics AB is a Sweden-based company developing gene tests. The Company's business model and concept is to manufacture, market and sell the Prostatype Test System as one prognostic package consisting of the Prostatype RTqPCR kit, the patient database and the evaluation software and accessories P-score. The test is supposed to check the aggressiveness of the prostate cancer in order to help clinicians and patients to make correct treatment decisions. Prostatype analyzes the gene expression in cancer cells extracted from prostate tissue and gives, in combination with an advanced algorithm and data analysis, decision support for optimal treatment of individual patients once prostate cancer has been confirmed.

Number of employees: 5

SEK in Million	2021	Weight	2022	Weight	Delta
Prognostic Methods 100.0 %	0	100.0 %	1	100.0 %	+6,727.30%

SEK in Million	2021	Weight	2022	Weight	Delta
Sweden 100.0 %	0	100.0 %	1	100.0 %	+6,727.30%

Managers	Title	Age	Since
Fredrik Persson CEO	Chief Executive Officer	-	16-12-31
Lars Anders Koch DFI	Director of Finance/CFO	-	23-10-30
Emelie Berglund CTO	Chief Tech/Sci/R&D Officer	-	-
Gerald Andriole CTO	Chief Tech/Sci/R&D Officer	-	23-05-04
Michael af Winklerfelt COO	Chief Operating Officer	52	19-12-31
Katarina Sjoberg LAW	General Counsel	-	-

Members of the board	Title	Age	Since
Karlheinz Schmelig BRD	Director/Board Member	-	12-12-31
Bengt Håkan Englund BRD	Director/Board Member	72	18-12-31
Michael Häggman BRD	Director/Board Member	-	17-12-31
Anders Lundberg CHM	Chairman	-	16-12-31
Mattias Prage BRD	Director/Board Member	-	21-12-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	119,460,000	14,952,566 ( 12.52 %)	0	12.52 %

Prostatype Genomics AB

Industrivägen 19

171 48, Solna

http://www.prostatypegenomics.com

Company calendar

Healthcare

Healthcare Services

Healthcare Providers & Services

Healthcare Facilities & Services

Medical & Diagnostic Laboratories

	1st Jan change	Capi.
PROSTATYPE GENOMICS AB	-56.21%	3.52M
SONIC HEALTHCARE LIMITED	-16.55%	8.43B
RADNET, INC.	+39.80%	3.62B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-38.71%	2.61B
SYNLAB AG	-7.88%	2.48B
DR. LAL PATHLABS LIMITED	-7.96%	2.34B
NEOGENOMICS, INC.	-13.91%	1.94B
FLEURY S.A.	-19.40%	1.56B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-38.35%	1.26B
METROPOLIS HEALTHCARE LIMITED	+6.91%	1.1B

Medical & Diagnostic Laboratories